Zhao T, Yang W, Pan F, Wang J, Shao W, Chen F
Front Endocrinol (Lausanne). 2025; 16:1514105.
PMID: 39936102
PMC: 11810737.
DOI: 10.3389/fendo.2025.1514105.
Lebachelier de la Riviere M, Teteau O, Mahe C, Lasserre O, Desmarchais A, Uzbekova S
BMC Genomics. 2024; 25(1):1095.
PMID: 39550580
PMC: 11568600.
DOI: 10.1186/s12864-024-11034-2.
Abubakar M, Irfan U, Abdelkhalek A, Javed I, Khokhar M, Shakil F
J Cardiovasc Transl Res. 2024; 17(6):1258-1285.
PMID: 38995611
DOI: 10.1007/s12265-024-10540-8.
Borja M, Hammerson B, Tang C, Juarez-Serrano L, Savinova O, Harris W
PLoS One. 2024; 19(2):e0296052.
PMID: 38408107
PMC: 10896500.
DOI: 10.1371/journal.pone.0296052.
Ogunbowale A, Georgieva E
Int J Mol Sci. 2024; 25(4).
PMID: 38397029
PMC: 10889703.
DOI: 10.3390/ijms25042354.
Esterified Oxylipins: Do They Matter?.
Annevelink C, Walker R, Shearer G
Metabolites. 2022; 12(11).
PMID: 36355090
PMC: 9697791.
DOI: 10.3390/metabo12111007.
Chemistory of Fibrates.
Balendiran G, Verma M, Perry E
Curr Chem Biol. 2021; 1(3):311-316.
PMID: 34485047
PMC: 8412053.
DOI: 10.2174/187231307781662198.
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis.
Lee C, Liao C, Meng S, Wu W, Chiang J, Wu M
Biomedicines. 2021; 9(8).
PMID: 34440189
PMC: 8393881.
DOI: 10.3390/biomedicines9080985.
Intestinal and Hepatic Uptake of Dietary Peroxidized Lipids and Their Decomposition Products, and Their Subsequent Effects on Apolipoprotein A1 and Paraoxonase1.
Jiang X, Deme P, Gupta R, Litvinov D, Burge K, Parthasarathy S
Antioxidants (Basel). 2021; 10(8).
PMID: 34439506
PMC: 8389297.
DOI: 10.3390/antiox10081258.
The ins and outs of lipid rafts: functions in intracellular cholesterol homeostasis, microparticles, and cell membranes: Thematic Review Series: Biology of Lipid Rafts.
Ouweneel A, Thomas M, Sorci-Thomas M
J Lipid Res. 2021; 61(5):676-686.
PMID: 33715815
PMC: 7193959.
DOI: 10.1194/jlr.TR119000383.
Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential.
Di L, Maiseyeu A
Drug Deliv. 2021; 28(1):408-421.
PMID: 33594923
PMC: 7894439.
DOI: 10.1080/10717544.2021.1886199.
Apolipoprotein A2 Isoforms: New Insight into the Risk of Myocardial Infarction.
Hisamatsu T
J Atheroscler Thromb. 2020; 28(5):469-470.
PMID: 33191315
PMC: 8193773.
DOI: 10.5551/jat.ED150.
Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence.
Raut S, Garud A, Nagarajan B, Sabnis N, Remaley A, Fudala R
J Pharmacol Exp Ther. 2020; 373(1):113-121.
PMID: 31941718
PMC: 7160862.
DOI: 10.1124/jpet.119.262899.
The Mechanism of Bisphenol A Atherogenicity Involves Apolipoprotein A-I Downregulation through NF-κB Activation.
Trusca V, Dumitrescu M, Fenyo I, Tudorache I, Simionescu M, Gafencu A
Int J Mol Sci. 2019; 20(24).
PMID: 31842455
PMC: 6941038.
DOI: 10.3390/ijms20246281.
The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β-Amyloid Efflux Across the Blood-Brain Barrier .
Dal Magro R, Simonelli S, Cox A, Formicola B, Corti R, Cassina V
Front Neurosci. 2019; 13:419.
PMID: 31156358
PMC: 6532439.
DOI: 10.3389/fnins.2019.00419.
Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus.
Block R, Holub A, Abdolahi A, Tu X, Mousa S, Oda M
Prostaglandins Leukot Essent Fatty Acids. 2017; 126:25-31.
PMID: 29031392
PMC: 5683419.
DOI: 10.1016/j.plefa.2017.08.016.
Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease.
Borja M, Hammerson B, Tang C, Savinova O, Shearer G, Oda M
PLoS One. 2017; 12(8):e0182217.
PMID: 28767713
PMC: 5540550.
DOI: 10.1371/journal.pone.0182217.
Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio.
Kaul S, Xu H, Zabalawi M, Maruko E, Fulp B, Bluemn T
J Am Heart Assoc. 2016; 5(11).
PMID: 27821400
PMC: 5210328.
DOI: 10.1161/JAHA.116.004401.
CC-Chemokine Ligand 2 (CCL2) Suppresses High Density Lipoprotein (HDL) Internalization and Cholesterol Efflux via CC-Chemokine Receptor 2 (CCR2) Induction and p42/44 Mitogen-activated Protein Kinase (MAPK) Activation in Human Endothelial Cells.
Sun R, Huang C, Bao J, Jiang J, Zhang B, Zhou S
J Biol Chem. 2016; 291(37):19532-44.
PMID: 27458015
PMC: 5016689.
DOI: 10.1074/jbc.M116.714279.
Microdomains, Inflammation, and Atherosclerosis.
Sorci-Thomas M, Thomas M
Circ Res. 2016; 118(4):679-91.
PMID: 26892966
PMC: 5291489.
DOI: 10.1161/CIRCRESAHA.115.306246.